Vancouver Coastal Health VA: VGH / UBCH / GFS

VC: BP / Purdy / GPC					
ORDERS				DDRESSOGRAPH	
			STATUS PRIOR TO WE		
			APY – OUTPATIE		
(MITOXANTI	RONE, ETOPO	•	SALVAGE THERAPY FO	OR REFRACTO	
		(Items with check boxes mu	ist be selected to be ordered)		(Page 1 of 3)
Date:		Time:			Time Processed RN/LPN Initials
□ 3	16 1 41				Comments
Consent signed	d for chemotherap) y			
			person of child bearing potenti	al has been	
assessed for th	he possibility of pre	gnancy.			
			_		
Prescriber's sig	gnature	Printed name	College ID		
		Chemotherapy Dosing C	alculations		
		Onemotherapy Bosing C	aiodiations		
Height:			Actual Weight:		
			Form and must be co-signed	by 2 nurses	
$BMI(kg/m^2) =$	$= \frac{Weight(kg)}{[Height(m)]^2}$	OR	BMI =	ka/ m²	
		ucational/lose_wt/BMI/bmi-m			
			.11011		
$BSA(m^2) = $	$\frac{\textit{Height}(cm) \times \textit{W}}{3600}$	reigni(kg)	BSA =	m²	
Round all BSA o	calculations to 2 de	cimal places ual weight or BSA to calcula	ate chemotherany doses		
	OSC dott	an weight of box to onloud	ate offernotherapy acces		
MONITORING:	Vital signs with e	each visit			
	Weight once wee	ekly			
	If temperature gr	eater than 38°C, notify Hema	tology Associate/Fellow for ini	itiation of antibiotics	3
	Complete signat	ure screening sheet for cytara	abine cerebellar toxicity prior to	o each cytarabine o	lose
SUDDODTIVE CADE	i. No onomos oun	positories, IM injections			
SUFFORTIVE CARE	•	positories, in injections steroidal anti-inflammatory dru	ine (NSAIDe)		
	No Non or non c	norolaar ariti iimaminatory are	190 (140/ 11 <i>2</i> 0)		
LABORATORY:	On each visit:				
	CBC with	differential, electrolytes, urea	, creatinine		
	On day 1, 3, 5, th	hen weekly:			
	GGT, ALT	, AST, alkaline phosphatase,	LDH, bilirubin (total & direct)		
	On day 1, then w	veekly:	,		
	INR, calciu	ım, magnesium, albumin			
	On day 1 to 3:				
	uric acid, o	calcium, phosphate			
Prescriber's Signatu	ire	Printed Name		ollege ID	
		VCH VA PPO 936 I I	Rev.IIII 2022		

IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604 -875-4077 IMMEDIATELY



VC: BP / Purdy / GPC

936

ORDERS

ADDRESSOGRAPH

COMPLETE OR REVIEW ALLERGY STATUS PRIOR TO WRITING ORDERS

AML MEC CHEMOTHERAPY – OUTPATIENT Orders (MITOXANTRONE, ETOPOSIDE, CYTARABINE) SALVAGE THERAPY FOR REFRACTORY LEUKEMIA

(IVIII OXAI)	(items with check boxes must be selected to be ordered)	(Page 2 of 3)		
Date:	Time:	Time Processed RN/LPN Initials Comments		
PREMEDICATIONS:				
ondansetron 8 mg PO 30 minutes prior to the first dose of chemotherapy on Day 1 to 5 *AND*				
dexamethasone 8 mg PO 30 minutes prior to the first dose of chemotherapy on Day 1 to 5				
INTRAVENOUS:				
sodium ch	loride 0.9% 1000 mL IV over 1 to 2 hours starting 30 minutes prior to the first dose of chemotherapy on Day 1 to 5			
CHEMOTHERAPY	' :			
BCCA Code for PC	CIS order entry: LKNOS			
All intensive chem	otherapy orders require 2 prescriber signatures, one of whom must be an attending physician			
mitoXANtr	one (8 mg/m², rounded to nearest 1 mg) mg IV over 15 minutes daily for 5 days.			
From	Day 1 (date): to Day 5 (date):			
etoposide	(100 mg/m², rounded to nearest 5 mg) mg IV over 1 hour daily for 5 days.			
Give	immediately after mitoXANtrone. From Day 1 (date): to Day 5 (date):			
cytarabine	(1000 mg/m², rounded to nearest 100 mg) mg IV over 1 hour daily for 5 days.			
Give	immediately after etoposide. From Day 1 (date): to Day 5 (date):			
SUPPORT MEDIC	ATIONS:			
Patient to take	own supply: Nurse to confirm:			
	asone 0.1% ophthalmic drops 2 drops in each eye Q6H starting immediately before the first dose of abine and continue until 48 hours after the last dose of cytarabine.			
Antiemetics:	 □ prochlorperazine 10 mg PO Q6H PRN breakthrough nausea and vomiting □ metoclopramide 10 to 20 mg PO/IV Q6H PRN breakthrough nausea and vomiting □ LORazepam 1 mg PO/IV Q6H PRN breakthrough nausea and vomiting 			
	as per completed FEBRILE NEUTROPENIA – OUTPATIENT INITIAL MANAGEMENT (PPO 310) PRE- PRINTED Orders			
Book appointments	s for chemotherapy administration			
Book first appointn	nent after completion of chemotherapy on (date):			
Prescriber's Sign	ature Printed Name College ID VCH.VA.PPO.936 Rev.JUL.2022			



VC: BP / Purdy / GPC

ORDERS

ADDRESSOGRAPH

	COMPLETE OR REVIEW ALLERGY STATUS PRIOR TO WRITING ORDERS				
(MITOXA	AML MEC CHEMOTHERAPY – OUTPATIENT Orders NTRONE, ETOPOSIDE, CYTARABINE) SALVAGE THERAPY FOR REFRACTOR				
Date:	(items with check boxes must be selected to be ordered) Time:	(Page 3 of 3) Time Processed RN/LPN Initials Comments			
SUPPORT MEDIC	CATIONS, continued:				
Provide prescrip	ntion for the following, if applicable:				
☐ allopurinol	300 mg PO DAILY x 10 days				
For all patients,	provide prescriptions for:				
Eye care:	dexamethasone 0.1% ophthalmic drops – 2 drops in each eye Q6H starting immediately before first dose of cytarabine and continue until 48 hours after last dose of cytarabine (10 mL)				
Mouth care:	chlorhexidine 0.12% oral rinse, 15 mL swish & spit BID (500 mL)				
Antiviral:	If HSV seropositive: ☐ valACYclovir 500 mg PO BID, starting when ANC below 0.5 x 10 ⁹ /L				
Antifungal:	fluCONazole 400 mg PO daily x 21 days, starting when ANC below 0.5 x 109/L				
Antibiotic:	ciprofloxacin 500 mg PO BID x 21 days, starting when ANC below 0.5 x 10 ⁹ /L *PLUS*				
	penicillin V 300 mg PO QID x 21 days, starting when ANC below 0.5 x 109/L				
	OR				
	amoxicillin-clavulanate 875-125 mg PO BID x 21 days, starting when ANC below 0.5 x 10 ⁹	/L			
Breakthrough nausea & vomiting: metoclopramide 20 mg PO Q4 to 6H PRN x 20 doses *OR*					
	prochlorperazine 10 mg PO Q4 to 6H PRN x 20 doses				
 NOTES TO PRESCRIBER: Patients with a history of invasive pulmonary aspergillosis or with prolonged neutropenia due to chemotherapy prior to initiation of MEC chemotherapy should receive prophylaxis with posaconazole (complete Special Authority Form). Start on day 6. Patients who are being treated for invasive pulmonary aspergillosis should continue antifungal therapy throughout chemotherapy. If HbsAg or Anti-HBc positive continue lamiVUDine 100 mg PO DAILY (complete Special Authority Form). Refer to L/BMT Manual for recommended duration of therapy and frequency of hepatitis B viral DNA level monitoring. 					
Prescriber's Sign	nature Printed Name College ID VCH.VA.PPO.936 I Rev.JUL.2022				